DMAC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 11, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 50 instances where the indicator turned negative. In 44 of the 50 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.
The 10-day RSI Indicator for DMAC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DMAC as a result. In 79 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
DMAC moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DMAC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where DMAC advanced for three days, in 219 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 139 of 169 cases where DMAC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. DMAC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.166) is normal, around the industry mean (3.596). P/E Ratio (-13.000) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The RSI Oscillator for IRD moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 24 of the 26 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for IRD just turned positive on November 03, 2026. Looking at past instances where IRD's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where IRD advanced for three days, in 215 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
IRD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRD as a result. In 92 of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for IRD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-26.779) is normal, around the industry mean (3.596). P/E Ratio (-3.240) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. IRD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DMAC | IRD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 38 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 38 | 40 | |
P/E GROWTH RATING 1..100 | 84 | 86 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IRD's Valuation (5) in the null industry is somewhat better than the same rating for DMAC (69) in the Biotechnology industry. This means that IRD’s stock grew somewhat faster than DMAC’s over the last 12 months.
DMAC's Profit vs Risk Rating (38) in the Biotechnology industry is somewhat better than the same rating for IRD (100) in the null industry. This means that DMAC’s stock grew somewhat faster than IRD’s over the last 12 months.
DMAC's SMR Rating (99) in the Biotechnology industry is in the same range as IRD (100) in the null industry. This means that DMAC’s stock grew similarly to IRD’s over the last 12 months.
DMAC's Price Growth Rating (38) in the Biotechnology industry is in the same range as IRD (40) in the null industry. This means that DMAC’s stock grew similarly to IRD’s over the last 12 months.
DMAC's P/E Growth Rating (84) in the Biotechnology industry is in the same range as IRD (86) in the null industry. This means that DMAC’s stock grew similarly to IRD’s over the last 12 months.
| DMAC | IRD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 74% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 82% |
| Advances ODDS (%) | 4 days ago 85% | 5 days ago 83% |
| Declines ODDS (%) | 6 days ago 81% | 9 days ago 82% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DMAC’s FA Score shows that 0 FA rating(s) are green while IRD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DMAC’s TA Score shows that 4 TA indicator(s) are bullish while IRD’s TA Score has 5 bullish TA indicator(s).
DMAC (@Biotechnology) experienced а -6.14% price change this week, while IRD (@Biotechnology) price change was +0.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
DMAC is expected to report earnings on Mar 23, 2027.
IRD is expected to report earnings on Mar 11, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with VIR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then VIR could also see price increases.
| Ticker / NAME | Correlation To DMAC | 1D Price Change % | ||
|---|---|---|---|---|
| DMAC | 100% | +2.87% | ||
| VIR - DMAC | 46% Loosely correlated | -5.41% | ||
| EDIT - DMAC | 46% Loosely correlated | -4.09% | ||
| ANNX - DMAC | 46% Loosely correlated | -9.09% | ||
| IMMX - DMAC | 45% Loosely correlated | -1.14% | ||
| SLDB - DMAC | 44% Loosely correlated | -2.95% | ||
More | ||||
A.I.dvisor indicates that over the last year, IRD has been loosely correlated with ARRY. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IRD jumps, then ARRY could also see price increases.
| Ticker / NAME | Correlation To IRD | 1D Price Change % | ||
|---|---|---|---|---|
| IRD | 100% | -2.21% | ||
| ARRY - IRD | 35% Loosely correlated | -9.67% | ||
| PRME - IRD | 35% Loosely correlated | -7.55% | ||
| DMAC - IRD | 34% Loosely correlated | +2.87% | ||
| FDMT - IRD | 33% Loosely correlated | -4.57% | ||
| SRPT - IRD | 33% Loosely correlated | -5.93% | ||
More | ||||